2026 NPPES data Ph.D. Medical Genetics NPI 1811991342 M.D.
Verify on CMS →

MYRA HALL, M.D.

Ph.D. Medical Genetics in ABERDEEN, North Carolina. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.

Federal data — no proprietary rating. PlainDoctor publishes the actual CMS NPPES and Medicare records — NPI registration, specialty, practice location, and prescribing data — without a composite score or editorial opinion on top. Every field traces to a federal source.
Prescribing volume
1K
Medicare Part D claims · 53 beneficiaries · Ph.D. Medical Genetics avg: 984
Generic prescribing
90%
generic claims · 10% brand-name · higher generic rates reduce patient out-of-pocket costs
Industry payments
$379.42
7 payments · CMS Open Payments (Sunshine Act)

What the federal data shows

MYRA HALL, M.D. filed 1,326 Medicare Part D claims in 2023 as a Ph.D. Medical Genetics in ABERDEEN, North Carolina, prescribing 90% generic.

1K
Part D claims, 2023
90%
generic prescribing
$379.42
industry payments (Sunshine Act)

Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.

MYRA HALL, M.D.'s Medicare Part D volume vs every U.S. prescriber

Total Medicare Part D claims, 2023 — across all CMS prescribers nationally

1,326 Top 21% higher than 79% of 1,370,886 prescribers

0–200: 670,926 prescribers (49%). Below this entry. 200–400: 182,923 prescribers (13%). Below this entry. 400–600: 90,619 prescribers (7%). Below this entry. 600–800: 56,224 prescribers (4%). Below this entry. 800–1,000: 40,919 prescribers (3%). Below this entry. 1,000–1,200: 31,827 prescribers (2%). Below this entry. 1,200–1,400: 26,224 prescribers (2%). This entry sits in this band. 1,400–1,600: 21,710 prescribers (2%). Above this entry. 1,600–1,800: 19,072 prescribers (1%). Above this entry. 1,800–2,000: 16,451 prescribers (1%). Above this entry. 2,000–2,200: 213,991 prescribers (16%). Above this entry. This provider 0 2K+ every Part D prescriber (claims/yr), bucketed by value

Each bar is a band; taller bars hold more prescribers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Medicare Part D Prescriber Public Use File · 2023

What does the federal data show about MYRA HALL, M.D.?

Quality data not reported

NPI registry status

Active

Issued 06/13/2005

NPI 1811991342

Primary specialty

Ph.D. Medical Genetics

Rare

357 US NPIs in this specialty

Medicare Part D claims

1,326 35% vs specialty avg

2023 prescription claims

Specialty avg: 984

Specialty distribution in North Carolina

How Ph.D. Medical Genetics compares to other specialties among North Carolina providers

North Carolina providers

Ph.D. Medical Genetics share within North Carolina

1. Ph.D. Medical Genetics42%2. Internal medicine21%3. Family medicine17%4. Surgical12%5. Pediatric8%
Ph.D. Medical Genetics share within North Carolina

Specialty board-certification context

Estimated specialty board-certified rate — Ph.D. Medical Genetics (ABMS / AOA reference)

Quality data not reported
Est. board-certified rate
78%
Ph.D. Medical Genetics ABMS/AOA estimate

Est. board-certified rate (Ph.D. Medical Genetics) — ABMS / AOA estimate

0%100%78%
Est. board-certified rate (Ph.D. Medical Genetics) — ABMS / AOA estimate

The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.

Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).

MYRA HALL, M.D. is a Ph.D. Medical Genetics provider practicing in ABERDEEN, North Carolina, according to the CMS National Plan and Provider Enumeration System (NPPES). Credentials: M.D.. NPI: 1811991342. This profile includes practice location, specialty classification, and organizational affiliations from the CMS provider registry. Provider information is self-reported to CMS and updated monthly.

MYRA HALL, M.D. appears in the CMS NPPES registry as a Ph.D. Medical Genetics provider holding M.D. credentials at 210 MAGNOLIA SQUARE COURT, ABERDEEN, NC, 28315, with a listed phone of (910) 944-0779. NPI 1811991342 was issued on 06/13/2005. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what HALL most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.

Medicare Part D records for calendar year 2023 show 1,326 prescription claims written by this provider, covering 53 Medicare beneficiaries and totaling roughly $95K in drug spend, split 10% brand-name and 90% generic by claim count, with an opioid prescribing rate of 13.0%. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy.

Ph.D. Medical Genetics is a narrow specialty nationwide, with 357 enrolled providers across 46 states and an average of 984 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.

Practice Address

210 MAGNOLIA SQUARE COURT
ABERDEEN, NC 28315

Provider Details

NPI 1811991342
Specialty Ph.D. Medical Genetics
Credentials M.D.
Gender Female
NPI Issued 06/13/2005

Industry payments received (2024) — CMS Open Payments transparency data

The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for MYRA HALL, M.D.. Source: openpaymentsdata.cms.gov.

Total received

$379

Largest payer

Lilly USA, LLC

Most common payment type

Food and Beverage

Industry payments are not necessarily indicators of bias — they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.

Brand vs generic prescribing mix · Typical

MYRA HALL, M.D. — brand share 10.0%
Specialty average (est.)

10% brand-name claims vs 90% generic, on 1,326 2023 Medicare Part D claims.

The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.

Medicare Part D Prescribing Data

CMS Medicare Part D prescriber-level data for calendar year 2023.

1,326
Total Claims
$95K
Total Drug Cost
53
Medicare Beneficiaries

Prescribing Breakdown

30-Day Fills
2,253
Total Day Supply
63,670
Brand vs Generic
10% brand / 90% generic
Brand Drug Cost
$71K
Generic Drug Cost
$24K
Opioid Claims
172 (13.0% rate)
Antibiotic Claims
28

Patient Demographics

Average Patient Age
71.2 years
Avg HCC Risk Score
0.76
Gender Split
62% female / 38% male

Top Prescribed Drugs (Medicare Part D)

Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.

Drug Claims
Oxycodone-Acetaminophen
Oxycodone Hcl/Acetaminophen
74
Rosuvastatin Calcium
67
Amlodipine Besylate
51
Lisinopril
49
Methadone Hcl
49
Levothyroxine Sodium
46
Alprazolam
44
Atorvastatin Calcium
39
Ondansetron Odt
Ondansetron
36
Gabapentin
34

* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.

Ph.D. Medical Genetics Overview

How MYRA HALL, M.D. fits within the Ph.D. Medical Genetics landscape nationally.

357
Ph.D. Medical Genetics Providers in US
46
States with Ph.D. Medical Genetics
984
Avg Claims per Provider

MYRA HALL, M.D.'s 1,326 claims are above the specialty average of 984.

Nearby Ph.D. Medical Genetics Providers in North Carolina

Other clinicians with the same primary specialty enrolled in North Carolina, drawn from the same CMS NPPES roster as HALL.

Compare Ph.D. Medical Genetics nationally: see state-by-state distribution →

Frequently Asked Questions

What is MYRA HALL, M.D.'s specialty?
MYRA HALL, M.D. specializes in Ph.D. Medical Genetics and practices in ABERDEEN, North Carolina. Credentials: M.D..
How much does MYRA HALL, M.D. prescribe under Medicare Part D?
In 2023, MYRA HALL, M.D. wrote 1,326 Medicare Part D claims totaling $95K in drug costs for 53 beneficiaries.
Where is MYRA HALL, M.D. located?
MYRA HALL, M.D. is located at 210 MAGNOLIA SQUARE COURT, ABERDEEN, NC, 28315. Phone: (910) 944-0779.
What is MYRA HALL, M.D.'s NPI number?
MYRA HALL, M.D.'s National Provider Identifier (NPI) is 1811991342, issued on 06/13/2005.
Does MYRA HALL, M.D. prescribe more brand-name or generic drugs?
MYRA HALL, M.D.'s prescribing is 10% brand-name and 90% generic drugs by claim count, with $71K in brand drug costs.
Does MYRA HALL, M.D. prescribe opioids?
Yes, MYRA HALL, M.D. had 172 opioid claims in 2023 with an opioid prescribing rate of 13.0%.
How many Ph.D. Medical Genetics providers are there in the US?
There are 357 Ph.D. Medical Genetics providers across 46 states in the US. The average Ph.D. Medical Genetics provider writes 984 Medicare Part D claims per year.
What drugs does MYRA HALL, M.D. prescribe most often?
Based on 2023 Medicare Part D data, MYRA HALL, M.D.'s most frequently prescribed drugs include Oxycodone-Acetaminophen, Rosuvastatin Calcium, Amlodipine Besylate. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does MYRA HALL, M.D. accept Medicare?
MYRA HALL, M.D. appears in CMS Medicare data with 1,326 Part D claims and 53 Medicare beneficiaries in 2023. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify MYRA HALL, M.D.'s credentials?
MYRA HALL, M.D.'s NPI is 1811991342 with credentials M.D.. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.

Data Sources

Provider Directory
CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
Specialty Classification
NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
Prescribing Data
CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
Limitations
Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.

See our complete data methodology for details on how we collect and process government data.

Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).

Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology